VEL-0230, also known as NC-2300, is a potent cathespin K inhibitor. VEL-0230 has dual-acting properties that both stimulates bone formation and inhibits loss. VEL-0230 is being studied preclinically for the treatment of diseases involving bone mineral disorders such as bone loss related to multiple myeloma, osteoporosis, bone metastases, and rheumatoid arthritis. Velcura Therapeutics is currently being developed by Velcura Therapeutics. Given VEL- 0230's promotion of bone formation, inhibition of bone loss and reduction of calcium levels, Velcura has chosen Myeloma as its lead indication, as the bone fragility, bone pain, high calcium levels and eventual kidney involvement present serious medical and quality of life issues to affected patients.
Prostaglandin E1 (PGE1), though not predominantly found in nature, plays a significant role in clinical treatments, addressing conditions such as peripheral occlusive vascular disease, erectile dysfunction, and neonatal cardiology issues. The metabolism of PGE1 primarily begins with the oxidation at C-15, producing 13,14-dihydro-15-keto PGE1 as its major metabolite. Alternatively, inhibiting this pathway or overwhelming it with too much PGE1 could potentially enhance the production of 2,3-dinor metabolites, like 2,3-dinor PGE1, though their biological activities remain unreported. Cayman Chemical stands out as a prominent provider of prostaglandins and their metabolites, uniquely manufacturing 2,3-dinor PGE1.
Bisphenol A-d14 是 Bisphenol A 的氘代标记形式。Bisphenol A 是一种酚类有机合成化合物,广泛用于制造聚碳酸酯塑料和环氧树脂。它被认为是一种具有生殖、发育和全身毒性的物质,通常被归类为内分泌干扰物 (EDC)。Bisphenol A 与多种疾病相关,包括心血管疾病、呼吸系统疾病、糖尿病、肾脏疾病、肥胖以及生殖障碍。
Bisphenol A-d6 是 Bisphenol A 的氘代物。Bisphenol A 是一种合成的酚类化合物,广泛用于制造聚碳酸酯塑料和环氧树脂。作为一种内分泌干扰物 (EDC),Bisphenol A 具有生殖、发育和全身毒性,可导致多种疾病,包括心血管疾病、呼吸系统疾病、糖尿病、肾脏疾病、肥胖以及生殖障碍。